COMMUNIQUÉS West-GlobeNewswire

-
Galapagos increases share capital through warrant exercises
23/11/2018 -
Quantity of shares in Nexstim Plc after completion of the first phase in reducing the quantity of shares
23/11/2018 -
Milestone Scientific Announces Recent Presentations Featuring The Wand® STA
23/11/2018 -
Abattis Bioceuticals Acquires Proprietary Genetic Strain Bank
23/11/2018 -
Mandatory notification of trade
23/11/2018 -
Oral semaglutide demonstrates favourable cardiovascular safety profile and significant reduction in cardiovascular death and all-cause mortality in people with type 2 diabetes in the PIONEER 6 trial
23/11/2018 -
ATW Tech Increases Its Revenues by 24% for Revenues of $3.1 Million for Its Third Quarter of 2018
23/11/2018 -
ATW Tech annonce des revenus en hausse de 24% pour 3,1 millions $ pour son troisième trimestre 2018
23/11/2018 -
Aura Closes Strategic Investment Into HolyCanna, Bolstering International Strategy
23/11/2018 -
Aleafia Closes Transactions with Serruya Private Equity
23/11/2018 -
Aleafia to Release Q3 Results on November 26
23/11/2018 -
Immunicum AB (publ) Publishes Prospectus in Connection with Rights Issue and Directed Issue
23/11/2018 -
BLOCK LISTING SIX MONTHLY RETURN
23/11/2018 -
Rule 2.9 Announcement
23/11/2018 -
Curetis Announces Financial Results for the First Nine Months of 2018
23/11/2018 -
Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease
23/11/2018 -
European Commission Approves Spark Therapeutics’ LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations
23/11/2018 -
Curetis Accelerates 510(k) Submission Preparation for Unyvero LRT in BAL Specimen Based on Positive FDA Feedback
23/11/2018 -
Sensorion Enters Into Exclusive Negotiations with Pasteur Institute for Hearing Loss Gene Therapy Programs
23/11/2018
Pages